- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.08. | Roth slashes price target on Longeveron | 3 | Cantech Letter | ||
| 14.08. | Longeveron reports Q2 results | 3 | Seeking Alpha | ||
| 13.08. | Longeveron Inc. Q2 Loss Declines | 1 | RTTNews | ||
| 13.08. | Longeveron Announces Second Quarter 2025 Financial Results and Provides Business Update | 256 | GlobeNewswire (Europe) | Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS... ► Artikel lesen | |
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 13.08. | Longeveron Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Preview: Longeveron's Earnings | 1 | Benzinga.com | ||
| 11.08. | Longeveron closes $5 million public offering of common stock | 2 | Investing.com | ||
| 11.08. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.08. | Longeveron Announces Closing Of Up To $17.5 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 08.08. | Longeveron Announces Up To $17.5 Million Public Offering | 8 | GlobeNewswire (USA) | ||
| 08.08. | Longeveron Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 04.08. | Longeveron launches offering of up to 11.8M shares via warrants and stock units | 4 | Seeking Alpha | ||
| 04.08. | Longeveron Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 21.07. | Longeveron Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease | 3 | GlobeNewswire (USA) | ||
| 09.07. | Longeveron Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 08.07. | Longeveron stock soars after FDA approves IND for heart failure treatment | 4 | Investing.com | ||
| 08.07. | Longeveron receives FDA approval for pediatric heart therapy IND | 2 | Investing.com | ||
| 08.07. | Longeveron Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) | 294 | GlobeNewswire (Europe) | Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated in first half of 2026Pediatric... ► Artikel lesen | |
| 26.06. | Longeveron Appoints Than Powell as Chief Business Officer | 159 | GlobeNewswire (Europe) | Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology... ► Artikel lesen | |
| 24.06. | Longeveron schließt Patientenrekrutierung für pädiatrische Herzstudie zu HLHS ab | 1 | Investing.com Deutsch |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,85 | +0,40 % | BioNTech Aktie: Kurssturz? - Circus, Commerzbank, Evotec, Puma und SFC Energy im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| CUREVAC | 4,584 | -0,22 % | CureVac Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| CRISPR THERAPEUTICS | 44,600 | -1,33 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
| OCUGEN | 0,894 | +1,50 % | Carisma Therapeutics stock soars after merger agreement with Ocugen | ||
| EDITAS MEDICINE | 2,155 | +1,36 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| CYTODYN | 0,252 | 0,00 % | CytoDyn Inc.: CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab | Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn's ongoing Phase II CRC trial Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,037 | +7,67 % | SOL Global Investments Corp.: SOL Global Appoints Hex Trust as Strategic Web3 Partner to Execute Institutional Digital Asset Strategy | Toronto, Ontario--(Newsfile Corp. - August 14, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") on 23 July, 2025, appointed Hex Trust, a leading... ► Artikel lesen | |
| TRINITY BIOTECH | - | - | XFRA NEW INSTRUMENTS AVAILABLE ON 27.08.2025 | The following instruments on XETRA do have their first trading 27.08.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 27.08.2025
Aktien
1 KYG694511059 Patria Investments Ltd.
2... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,883 | -0,79 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates | First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 8,000 | -2,39 % | Anavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update | Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,710 | 0,00 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| CERUS | 1,134 | +3,47 % | Cerus Corporation: The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions | Cerus Corporation (Nasdaq: CERS) announced today the publication of a new recommendation from the German National Blood Advisory Committee (Arbeitskreis Blut or AK Blut), which recommends proactive... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,108 | -1,82 % | Windtree Therapeutics: Aktionäre genehmigen Kapitalerhöhung und Aktienzusammenlegung | ||
| OVID THERAPEUTICS | 0,980 | -7,55 % | Ovid Therapeutics Inc.: Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties | NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions... ► Artikel lesen | |
| APTEVO THERAPEUTICS | 1,480 | 0,00 % | Aptevo Therapeutics: Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer | Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived... ► Artikel lesen |
LONGEVERON INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,822 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.